Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?
Aim. To assess prescribing practices of noninsulin antidiabetic drugs (NIADs) in T2DM with several major contraindications according to prescribing information or clinical guidelines: renal failure, heart failure, liver dysfunction, or history of bladder cancer. Methods. Cross-sectional, descriptive...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2016/7502489 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558090270015488 |
|---|---|
| author | Irene Ruiz-Tamayo Josep Franch-Nadal Manel Mata-Cases Dídac Mauricio Xavier Cos Antonio Rodriguez-Poncelas Joan Barrot Gabriel Coll-de-Tuero Xavier Mundet-Tudurí |
| author_facet | Irene Ruiz-Tamayo Josep Franch-Nadal Manel Mata-Cases Dídac Mauricio Xavier Cos Antonio Rodriguez-Poncelas Joan Barrot Gabriel Coll-de-Tuero Xavier Mundet-Tudurí |
| author_sort | Irene Ruiz-Tamayo |
| collection | DOAJ |
| description | Aim. To assess prescribing practices of noninsulin antidiabetic drugs (NIADs) in T2DM with several major contraindications according to prescribing information or clinical guidelines: renal failure, heart failure, liver dysfunction, or history of bladder cancer. Methods. Cross-sectional, descriptive, multicenter study. Electronic medical records were retrieved from all T2DM subjects who attended primary care centers pertaining to the Catalan Health Institute in Catalonia in 2013 and were pharmacologically treated with any NIAD alone or in combination. Results. Records were retrieved from a total of 255,499 pharmacologically treated patients. 78% of patients with some degree of renal impairment (glomerular filtration rate (GFR) < 60 mL/min) were treated with metformin and 31.2% with sulfonylureas. Even in the event of severe renal failure (GFR < 30 mL/min), 35.3% and 22.5% of patients were on metformin or sulfonylureas, respectively. Moreover, metformin was prescribed to more than 60% of patients with moderate or severe heart failure. Conclusion. Some NIADs, and in particular metformin, were frequently used in patients at high risk of complications when they were contraindicated. There is a need to increase awareness of potential inappropriate prescribing and to monitor the quality of prescribing patterns in order to help physicians and policymakers to yield better clinical outcomes in T2DM. |
| format | Article |
| id | doaj-art-43abd36d592441eaad8aceb431fd46a9 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-43abd36d592441eaad8aceb431fd46a92025-02-03T01:33:12ZengWileyJournal of Diabetes Research2314-67452314-67532016-01-01201610.1155/2016/75024897502489Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?Irene Ruiz-Tamayo0Josep Franch-Nadal1Manel Mata-Cases2Dídac Mauricio3Xavier Cos4Antonio Rodriguez-Poncelas5Joan Barrot6Gabriel Coll-de-Tuero7Xavier Mundet-Tudurí8Primary Health Care Center La Torrassa, Consorci Sanitari Integral, Ronda Torrassa 151-153, 08903 L’Hospitalet de Llobregat, SpainDAP-Cat Group, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Sardenya 375, 08006 Barcelona, SpainDAP-Cat Group, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Sardenya 375, 08006 Barcelona, SpainDAP-Cat Group, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Sardenya 375, 08006 Barcelona, SpainDAP-Cat Group, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Sardenya 375, 08006 Barcelona, SpainDAP-Cat Group, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Sardenya 375, 08006 Barcelona, SpainDAP-Cat Group, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Sardenya 375, 08006 Barcelona, SpainDAP-Cat Group, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Sardenya 375, 08006 Barcelona, SpainDAP-Cat Group, Unitat de Suport a la Recerca Barcelona Ciutat, Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Sardenya 375, 08006 Barcelona, SpainAim. To assess prescribing practices of noninsulin antidiabetic drugs (NIADs) in T2DM with several major contraindications according to prescribing information or clinical guidelines: renal failure, heart failure, liver dysfunction, or history of bladder cancer. Methods. Cross-sectional, descriptive, multicenter study. Electronic medical records were retrieved from all T2DM subjects who attended primary care centers pertaining to the Catalan Health Institute in Catalonia in 2013 and were pharmacologically treated with any NIAD alone or in combination. Results. Records were retrieved from a total of 255,499 pharmacologically treated patients. 78% of patients with some degree of renal impairment (glomerular filtration rate (GFR) < 60 mL/min) were treated with metformin and 31.2% with sulfonylureas. Even in the event of severe renal failure (GFR < 30 mL/min), 35.3% and 22.5% of patients were on metformin or sulfonylureas, respectively. Moreover, metformin was prescribed to more than 60% of patients with moderate or severe heart failure. Conclusion. Some NIADs, and in particular metformin, were frequently used in patients at high risk of complications when they were contraindicated. There is a need to increase awareness of potential inappropriate prescribing and to monitor the quality of prescribing patterns in order to help physicians and policymakers to yield better clinical outcomes in T2DM.http://dx.doi.org/10.1155/2016/7502489 |
| spellingShingle | Irene Ruiz-Tamayo Josep Franch-Nadal Manel Mata-Cases Dídac Mauricio Xavier Cos Antonio Rodriguez-Poncelas Joan Barrot Gabriel Coll-de-Tuero Xavier Mundet-Tudurí Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications? Journal of Diabetes Research |
| title | Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications? |
| title_full | Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications? |
| title_fullStr | Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications? |
| title_full_unstemmed | Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications? |
| title_short | Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications? |
| title_sort | noninsulin antidiabetic drugs for patients with type 2 diabetes mellitus are we respecting their contraindications |
| url | http://dx.doi.org/10.1155/2016/7502489 |
| work_keys_str_mv | AT ireneruiztamayo noninsulinantidiabeticdrugsforpatientswithtype2diabetesmellitusarewerespectingtheircontraindications AT josepfranchnadal noninsulinantidiabeticdrugsforpatientswithtype2diabetesmellitusarewerespectingtheircontraindications AT manelmatacases noninsulinantidiabeticdrugsforpatientswithtype2diabetesmellitusarewerespectingtheircontraindications AT didacmauricio noninsulinantidiabeticdrugsforpatientswithtype2diabetesmellitusarewerespectingtheircontraindications AT xaviercos noninsulinantidiabeticdrugsforpatientswithtype2diabetesmellitusarewerespectingtheircontraindications AT antoniorodriguezponcelas noninsulinantidiabeticdrugsforpatientswithtype2diabetesmellitusarewerespectingtheircontraindications AT joanbarrot noninsulinantidiabeticdrugsforpatientswithtype2diabetesmellitusarewerespectingtheircontraindications AT gabrielcolldetuero noninsulinantidiabeticdrugsforpatientswithtype2diabetesmellitusarewerespectingtheircontraindications AT xaviermundettuduri noninsulinantidiabeticdrugsforpatientswithtype2diabetesmellitusarewerespectingtheircontraindications |